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Background: Recent data have suggested possible oncologic equiva-
lence of sublobar resection with lobectomy for early-stage non–small-
cell lung cancer (NSCLC). Our aim was to evaluate and compare 
short-term and long-term survival for these surgical approaches.
Methods: This retrospective cohort study utilized the National 
Cancer Data Base. Patients undergoing lobectomy, segmentectomy, 
or wedge resection for preoperative clinical T1A N0 NSCLC from 
2003 to 2011 were identiﬁed. Overall survival (OS) and 30-day mor-
tality were analyzed using multivariable Cox proportional hazards 
models, logistic regression models, and propensity score matching. 
Further analysis of survival stratiﬁed by tumor size, facility type, 
number of lymph nodes (LNs) examined, and surgical margins was 
performed.
Results: A total of 13,606 patients were identiﬁed. After propensity 
score matching, 987 patients remained in each group. Both seg-
mentectomy and wedge resection were associated with signiﬁcantly 
worse OS when compared with lobectomy (hazard ratio: 1.70 and 
1.45, respectively, both p < 0.001), with no difference in 30-day mor-
tality. Median OS for lobectomy, segmentectomy, and wedge resec-
tion were 100, 74, and 68 months, respectively (p < 0.001). Finally, 
sublobar resection was associated with increased likelihood of posi-
tive surgical margins, lower likelihood of having more than three LNs 
examined, and signiﬁcantly lower rates of nodal upstaging.
Conclusion: In this large national-level, clinically diverse sample of 
clinical T1A NSCLC patients, wedge and segmental resections were 
shown to have signiﬁcantly worse OS compared with lobectomy. 
Further patients undergoing sublobar resection were more likely to 
have inadequate lymphadenectomy and positive margins. Ongoing 
prospective study taking into account LN upstaging and margin sta-
tus is still needed.
Key Words: Non–small-cell lung cancer, Lobectomy, Wedge resec-
tion, Segmentectomy, National Cancer Data Base.
(J Thorac Oncol. 2015;10: 1625–1633)
Anatomic surgical resection with a lobectomy and mediasti-nal lymph node (LN) staging is currently the standard ther-
apy with curative intent for clinical stage IA non–small-cell 
lung cancer (NSCLC).1,2 However, preexisting cardiopulmo-
nary disease may make the perceived morbidity and mortality 
associated with lobectomy prohibitive. In addition, lobectomy 
leads to signiﬁcant loss of normal lung parenchyma. Sublobar 
pulmonary resections, such as wedge resection and anatomical 
segmentectomy, have lower perioperative morbidity, preserve 
more pulmonary function, and in many cases allow for greater 
applicability of minimally invasive techniques. In fact, data 
from the Surveillance, Epidemiology and End Results (SEER) 
database indicate that as many as 31% of patients with local-
ized NSCLC do not undergo lobectomy.3 Several nonrandom-
ized retrospective case series and database analyses have been 
published comparing lobar and sublobar resections with mixed 
results, particularly in regards to tumors smaller than 2 cm.4–12
As a result, there is ongoing debate in regards to the 
optimal extent of surgical resection for early-stage lung 
cancer. Our aim was to examine overall survival (OS) and 
30-day survival among patients undergoing lobectomy, seg-
mentectomy, and wedge resection for stage 1 NSCLC 2 cm or 
smaller, through an analysis of the National Cancer Data Base 
(NCDB). We hypothesized that patients undergoing lobec-
tomy would have worse operative mortality, and therefore 
worse 30-day mortality, but better OS.
PATIENT AND METHODS
We performed a retrospective cohort study using the 
NCDB to compare operative outcomes including mortality 
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and long-term survival among patients who underwent lobec-
tomy, segmentectomy, and wedge resection for clinical stage 
IA NSCLC. The NCDB is a joint endeavor of the Commission 
on Cancer (CoC) of the American College of Surgeons and the 
American Cancer Society. It includes registry-level clinical 
and demographic detail on patients treated at approximately 
1500 CoC-approved hospitals across the country. Cases were 
identiﬁed using the NSCLC Participant Use Data ﬁle from 
the NCDB, which contain deidentiﬁed patient level data that 
do not identify hospitals, health care providers, or patients. 
Institutional review board approval was waived by the Emory 
University institutional review board.
Patients diagnosed between 2003 and 2011 with clinical 
stage IA NSCLC who underwent lobectomy, segmentectomy, 
or wedge resection were included in this analysis. Charlson/
Deyo comorbidity scores were not available before 2003; 
therefore, patients before this time point were excluded. All 
analyses of OS were limited to patients treated between 2003 
and 2006, as long-term survival data are not yet available in 
the NCDB for cases after 2006. In addition, the following 
exclusions were made: cases where the diagnosis was at the 
reporting facility and all treatment was done elsewhere, can-
cer in situ, palliative care cases, unknown laterality, patients 
receiving neoadjuvant radiation and those missing 30-day 
mortality or other secondary outcomes. Only cases with 
one lifetime cancer or cases where the reported tumor was 
the ﬁrst of multiple cancer diagnoses were included to avoid 
confounding with a prior cancer treatment or diagnosis. The 
patient selection/exclusion criteria and sample sizes are shown 
in Supplementary Table 1 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A887).
The primary outcome measures were OS, deﬁned as 
the number of months between surgical resection and the 
last contact or date of death, and 30-day mortality, deﬁned 
as death within 30 days of surgery. Secondary outcome mea-
sures included surgical margin status, number of regional 
LN examined (0–3 vs. >3), and regional LN positivity. The 
following patient demographics, clinical characteristics, and 
treatment characteristics were included as covariates in the 
analysis: facility type, sex, race, insurance, income, educa-
tion, urban/rural, Charlson/Deyo comorbidity score, year of 
diagnosis, primary site, histology, grade, age, and tumor size. 
Both income and education were measured as the median 
household income and percentile of not graduating from high 
school at the residence area of the patients when diagnosed by 
matching the zip code and 2000 US Census data. The facility 
type was determined by the CoC based on services provided 
and the number of cases.13 Community cancer programs treat 
between 100 and 500 cancer cases per year, comprehensive 
community cancer programs treat more than 500 cancer cases, 
and academic/research programs (including National Cancer 
Institute designated cancer centers) treat more than 500 cancer 
cases in addition to providing postgraduate medical education.
Statistical analysis was conducted using SAS Version 
9.3 (Cary, NC), and SAS macros and software developed 
by the Biostatistics and Bioinformatics Shared Resource at 
Winship Cancer Insititute.14 Descriptive statistics were pre-
sented as frequencies with percentages or as means with 
standard deviations for categorical or numerical variables, 
respectively. The univariate association of each covariate with 
extent of surgical resection and 30-day mortality were assessed 
using the χ2 test for categorical covariates and analysis of vari-
ance for numerical covariates. A multivariable logistic regres-
sion model for 30-day mortality was ﬁt. The univariate and 
multivariable association with OS was estimated using Cox 
proportional hazards models. A backward variable selection 
method was used in multivariable models to select covariates, 
applying an α value equal to 0.20 removal criteria. To explore 
whether the impact of extent of lung resection on OS dif-
fered by treatment facility types, tumor size (≤1 vs. 1–2 cm), 
number of regional LNs examined (≤7 vs. >7), and surgical 
margin status, an interaction between the stratus variable and 
extent of surgical resection was introduced into the multivari-
able model. Kaplan–Meier curves were generated to provide 
survival estimates for OS. All analyses of OS, as mentioned 
earlier, were done only on patients diagnosed between 2003 
and 2006. All statistical tests were two-sided and used an α 
value equal to 0.05 level of signiﬁcance.
A propensity score matching method was also imple-
mented to further eliminate treatment selection bias in the 
study sample. A nominal logistic regression model predicting 
extent of surgical resection was used to calculate propensity 
scores including all covariates. Cases from the three surgi-
cal resection groups were matched to each other based on 
the propensity scores using a nearest neighbor with caliper 
algorithm.15 The effectiveness of the matching was evaluated 
by calculating the pair wise standardized differences of the 
covariates on the matched sample.16 A standardized differ-
ence of less than 0.1 denoted negligible imbalance and was 
used to choose the caliper for matching. The treatment effects 
were recalculated in the matched sample with appropriate 
methods to account for the matched nature of data, such as 
stratiﬁed logistic or Cox regression.17 After matching, the 
baseline covariates, including facility type, sex, race, insur-
ance, income, education, urban/rural, Charlson/Deyo comor-
bidity score, year of diagnosis, primary site, histology, grade, 
age, and tumor size, were balanced among the three cohorts.
RESULTS
Twenty-eight thousand two hundred and forty-one 
patients in the NCDB were identiﬁed who underwent surgi-
cal resection for stage IA NSCLC and met inclusion crite-
ria. Nineteen thousand seven hundred and eighteen patients 
underwent lobectomy, 7297 underwent wedge resection, and 
1226 underwent segmental resection. Clinical details of the 
patients at the time of resection are shown in Table 1. When 
comparing the three cohorts, we identiﬁed several differences 
in baseline patient characteristics. Patients undergoing sub-
lobar resection (wedge resection or segmentectomy) were on 
average 3 years older and have higher Charlson comorbidity 
scores. In addition, there was a higher incidence of patients 
with government, and no insurance in those undergoing sub-
lobar resection. There were slight differences between the 
groups in regards to gender, race, treatment facility, income, 
tumor grade, histology, and primary site of tumor as shown 
in Table 1. No difference was identiﬁed in education levels. 
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TABLE 1. Comparison of Extent of Resection: Lobectomy, Wedge, and Segmental Resection
Covariate Level
Lobectomy (%), 
N = 19,718
Wedge  
Resection (%),  
N = 7297
Segmental  
Resection (%),  
N = 1226 P Value
Facility type Noncomprehensive community cancer 
program/other
1646 (8.4) 689 (9.4) 69 (5.6) <0.001
Comprehensive community cancer  
program
11,206 (56.8) 4018 (55.1) 659 (53.8)
Academic/research program (Includes NCI) 6866 (34.8) 2590 (35.5) 498 (40.6)
Patient age Mean ± stdandard deviation 65.8 ± 9.9 68.9 ± 9.8 68.7 ± 9.4 <0.001
Sex Male 8001 (40.6) 2937 (40.3) 444 (36.2) 0.010
Female 11,717 (59.4) 4360 (59.8) 782 (63.9)
Race: White No 2067 (10.6) 662 (9.2) 108 (8.9) <0.001
Yes 17,464 (89.4) 6570 (90.9) 1102 (91.1)
Insurance Not insured 319 (1.6) 92 (1.3) 12 (1.0) <0.001
Private insurance 7123 (36.6) 1940 (26.9) 400 (33.0)
Government insurance 12,026 (61.8) 5185 (71.8) 800 (66.0)
Income <$30,000 2372 (12.8) 908 (13.2) 139 (12.1) 0.047
$30,000–$34,999 3354 (18.1) 1285 (18.6) 214 (18.7)
$35,000–$45,999 5321 (28.7) 1938 (28.1) 283 (24.7)
$46,000 + 7505 (40.5) 2773 (40.2) 509 (44.5)
Education ≥29% 2841 (15.3) 1037 (15.0) 158 (13.8) 0.403
20–28.9% 4463 (24.1) 1711 (24.8) 261 (22.8)
14–19.9% 4615 (24.9) 1703 (24.7) 287 (25.1)
<14% 6632 (35.8) 2452 (35.5) 439 (38.3)
Urban/rural Metro area 15,091 (82.1) 5601 (81.7) 985 (86.6) <0.001
Urban/rural 3300 (17.9) 1251 (18.3) 153 (13.4)
Charlson/Deyo score 0 9849 (50.0) 3017 (41.4) 500 (40.8) <0.001
1 7293 (37.0) 2976 (40.8) 514 (41.9)
2+ 2576 (13.1) 1304 (17.9) 212 (17.3)
Primary site Left upper lobe 5115 (25.9) 2051 (28.1) 385 (31.4) <0.001
Left lower lobe 2545 (12.9) 1040 (14.3) 215 (17.5)
Right upper lobe 7204 (36.5) 2481 (34.0) 320 (26.1)
Right middle lobe 1441 (7.3) 348 (4.8) 32 (2.6)
Right lower lobe 3132 (15.9) 1219 (16.7) 253 (20.6)
Overlapping lesion of lung 73 (0.4) 34 (0.5) 2 (0.2)
Lung, NOS; Bronchus, NOS 208 (1.1) 124 (1.7) 19 (1.6)
Size of tumor (cm) Mean ± stdandard deviation 1.52 ± 0.39 1.4 ± 0.42 1.46 ± 0.40 <0.001
Histology Adenocarcinomas 13,097 (66.4) 4336 (59.4) 760 (62.0) <0.001
Adenosquamous carcinomas 419 (2.1) 173 (2.4) 27 (2.2)
Large-cell carcinomas 513 (2.6) 216 (3.0) 21 (1.7)
Squamous cell carcinomas 3957 (20.1) 1795 (24.6) 289 (23.6)
Other tumorsa 1136 (5.8) 499 (6.8) 90 (7.3)
Unknown histology 596 (3.0) 278 (3.8) 39 (3.2)
Grade 1 4140 (21.0) 1465 (20.1) 255 (20.8) <0.001
2 8944 (45.4) 3043 (41.7) 556 (45.4)
3–4 5262 (26.7) 2036 (27.9) 324 (26.4)
Unknown 1372 (7.0) 753 (10.3) 91 (7.4)
30-Day mortality 1.60% 1.51% 1.55% 0.868
Surgical margins Negative 19,436 (98.6) 7005 (96.0) 1200 (97.9) <0.001
Positive 282 (1.4) 292 (4.0) 26 (2.1)
Regional LN surgery performed No regional LN surgery 680 (3.5) 3721 (51.1) 258 (21.1) <0.001
Regional LN surgery 19,029 (96.6) 3560 (48.9) 965 (78.9)
(Continued)
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Further analysis of these socioeconomic differences has previ-
ously been reported.18 In addition, wedge resection and seg-
mentectomy were associated with several secondary outcome 
measures. Compared with lobectomy, wedge resection was 
associated with a 2.6% higher incidence of positive surgi-
cal margins, a 55% higher incidence of having three or less 
LN examined, and as a result, a 5% lower incidence of nodal 
upstaging. Segmentectomy was associated with a similar rate 
of positive margins when compared with lobectomy but was 
associated with a 33% higher incidence of having three or less 
LN examined and a 4% lower incidence of nodal upstaging.
The primary goals of this database analysis were the 
comparison of 30-day mortality and OS between patients 
undergoing lobectomy and sublobar resection. Overall, 30-day 
mortality was quite low at 1.60% for lobectomy, 1.51% for 
wedge resection, and 1.55% for segmental resection (p = 0.868, 
Table 1). However, on multivariate analysis, the odds of mor-
tality was slightly lower after wedge resection compared with 
lobectomy (Table 2, OR, 0.72; 95% conﬁdence interval [CI], 
0.57–0.90, p = 0.005). No difference was noted between seg-
mentectomy and lobectomy. The remainder of the results of the 
multivariable logistic regression analysis of 30-day mortality is 
TABLE 2. Multivariable Association with 30-Day Mortality
Covariate Level Odds Ratio (95% CI) P Value
Extent of lung resection Segmental resection 0.87 (0.54–1.42) 0.585
Wedge resection 0.72 (0.57–0.90) 0.005
Lobectomy — —
Facility type Academic/research program (Includes NCI) 0.58 (0.42–0.81) 0.001
Comprehensive community cancer program 0.68 (0.51–0.92) 0.012
Community cancer program/other — —
Sex Male 1.72 (1.41–2.09) <0.001
Female — —
Patient age 1.05 (1.03–1.06) <0.001
Insurance Not insured 2.05 (0.98–4.27) 0.056
Private insurance 0.76 (0.57–1.00) 0.054
Government insurance — —
Income <$30,000 1.27 (0.92–1.73) 0.141
$30,000–$34,999 1.42 (1.08–1.85) 0.011
$35,000–$45,999 1.32 (1.03–1.68) 0.027
$46,000+ — —
Charlson/Deyo score 2+ 1.44 (1.10–1.88) 0.007
1 1.09 (0.87–1.36) 0.443
0 — —
Histology Unknown histology 1.50 (0.93–2.43) 0.096
Squamous cell carcinomas 1.56 (1.25–1.94) <0.001
Other tumorsa 0.58 (0.28–1.17) 0.129
Large-cell carcinomas 1.31 (0.76–2.28) 0.332
Adenosquamous carcinomas 2.22 (1.37–3.59) 0.001
Adenocarcinomas — —
aIncluding but not restricted to, spindle cell carcinoma, mucoepidermoid malignancies, neuroendocrine, and mixed malignant tumors.
Year of diagnosis not shown here, but was included in the model and was associated with 30-day mortality.
CI, conﬁdence interval.
Nodal upstaging No 18,275 (92.7) 7147 (97.9) 1182 (96.4) <0.001
Yes 1443 (7.3) 150 (2.1) 44 (3.6)
Number of regional  
LN examined
0–3 4232 (21.5) 5574 (76.4) 662 (54.0) <0.001
>3 15,486 (78.5) 1723 (23.6) 564 (46.0)
Year of diagnosis was included in the model, but not shown here.
aIncluding but not restricted to, spindle cell carcinoma, mucoepidermoid malignancy.
LN, lymph node; NOS, not otherwise speciﬁed; NCI, National Cancer Institute.
TABLE 1. (Continued)
Covariate Level
Lobectomy (%), 
N = 19,718
Wedge  
Resection (%),  
N = 7297
Segmental  
Resection (%),  
N = 1226 P Value
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shown in Table 2. Male sex, older patient age, lower income, 
treatment at a noncomprehensive community cancer program, 
Charlson/Deyo comorbidity score of 2 or higher, older year of 
diagnosis, and squamous and adenosquamous cell histologies 
were all associated with higher 30-day mortality.
Unadjusted Kaplan–Meier survival curves compar-
ing extent of surgical resection demonstrated signiﬁcantly 
improved OS with lobectomy (p < 0.0001, Fig. 1A). Median 
OS for lobectomy, segmentectomy, and wedge resection were 
99.5 (95% CI, 96.8–105), 74 (95% CI, 65.7–87.4), and 67.9 
(95% CI, 63.6–71.3) months, respectively. After controlling 
for confounding factors, Cox proportional hazard model 
(Table 3) showed lobectomy was associated with signiﬁcantly 
improved OS compared with both wedge resection (hazard 
Extent of Lung 
Resection
No. of 
Subject Event Censored
Median 
Survival (95% 
CI) 60 mo Survival
Lobectomy 4857 1847 (38%) 3010 (62%) 99.5 (96.8, 105) 70.4% (69.0%, 71.7%)
Segmental Resection 286 147 (51%) 139 (49%) 74 (65.7, 87.4) 59.6% (53.5%, 65.2%)
Wedge Resection 1891 1044 (55%) 847 (45%) 67.9 (63.6, 71.3) 54.6% (52.3%, 56.9%)
Extent of Lung 
Resection
No. of 
Subject Event Censored
Median 
Survival (95% 
CI) 60 mo Survival
Lobectomy 209 81 (39%) 128 (61%) 94.5 (80.6, NA) 71.4% (64.4%, 77.3%)
Segmental Resection 209 107 (51%) 102 (49%) 73.7 (63.3, 92.6) 59.1% (51.9%, 65.5%)
Wedge Resection 209 121 (58%) 88 (42%) 67.9 (57.7, 77.1) 54.8% (47.6%, 61.3%)
A
B
FIGURE 1. Kaplan–Meier survival curves by extent 
of surgical resection in (A) unadjusted population 
and (B) propensity score matched sample.
1630 Copyright © 2015 by the International Association for the Study of Lung Cancer
Khullar et al. Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015
ratio [HR] = 1.54, 95% CI, 1.42–1.67, p < 0.001) and seg-
mentectomy (HR = 1.33, 95% CI, 1.11–1.60, p = 0.002). 
Other predictors of worse OS included treatment at a non-
comprehensive community cancer program, male sex, older 
age, government insurance, lower income, higher Charlson/
Deyo comorbidity score, advanced tumor grade, and larger 
tumor size.
The interaction between extent of resection with tumor 
size, treatment facility type, number of LN evaluated, and 
surgical margin status was then further evaluated (Table 4, 
Supplementary Figs. 1–4, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A888). After controlling for con-
founding variables, the inferiority of sublobar approaches to 
lobectomy persisted despite the number of LN examined and 
tumor size (Kaplan–Meier analysis shown in Supplementary 
Figs. 2 and 3, Supplemental Digital Content 2, http://links.
lww.com/JTO/A888). For each subgroup, the HR for long-
term survival remained worse after wedge or segmental resec-
tion. Although the HR for long-term survival was worse after 
segmental resection for tumors smaller than 1 cm (1.24), this 
result was not statistically signiﬁcant (p = 0.414). Given then 
relatively low sample size of segmentectomies in this cohort (n 
= 51), it is difﬁcult to draw further conclusions. Furthermore, 
when comparing stratiﬁcation levels for these two subgroup 
analyses, no signiﬁcant interaction was identiﬁed, as evidenced 
by type 3 p values of 0.203 for tumor size and 0.655 for number 
of regional LN examined. Furthermore, the interaction of extent 
of resection with number of LN examined was tested at 3, 5, 
and 7 LN, with the inferiority of wedge and segmental resec-
tions persisting at all levels. In regards to treatment facility type, 
OS after wedge resection continued to be inferior to lobectomy 
regardless of treatment facility type. This was conﬁrmed on 
Kaplan–Meier analysis (Supplementary Fig. 1, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A888). Similarly, 
segmentectomy remained inferior to lobectomy at noncom-
prehensive community programs and academic facilities, as 
well. However, no difference was identiﬁed between segmen-
tal resection and lobectomy at comprehensive community pro-
grams. Finally, no interaction was identiﬁed between extent of 
resection and surgical margin status. In patients with negative 
TABLE 3. Cox Proportional Hazard Model of Overall Survival
Covariate Level Hazard Ratio P Value
Extent of lung resection Segmental resection 1.33 (1.11–1.60) 0.002
Wedge resection 1.54 (1.42–1.67) <0.001
Lobectomy — —
Facility type Academic/research program (Includes NCI) 0.86 (0.75–0.99) 0.041
Comprehensive community cancer program 0.92 (0.80–1.05) 0.194
Community cancer program/other — —
Sex Male 1.24 (1.15–1.33) <0.001
Female — —
Patient age 1.03 (1.02–1.03) <0.001
Insurance Not insured 0.83 (0.56–1.23) 0.356
Private insurance 0.83 (0.76–0.92) <0.001
Govenment insurance — —
Income <$30,000 1.33 (1.18–1.50) <0.001
$30,000–$34,999 1.30 (1.17–1.44) <0.001
$35,000–$45,999 1.14 (1.04–1.25) 0.007
$46,000+ — —
Charlson/Deyo score 2+ 1.52 (1.36–1.69) <0.001
1 1.17 (1.08–1.27) <0.001
0 — —
Histology Unknown histology 1.16 (0.98–1.36) 0.080
Squamous cell carcinomas 1.06 (0.96–1.16) 0.246
Other tumorsa 0.78 (0.59–1.02) 0.074
Large-cell carcinomas 1.09 (0.90–1.33) 0.366
Adenosquamous carcinomas 1.18 (0.93–1.50) 0.171
Adenocarcinomas — —
Grade Unknown, high-grade dysplasia 1.33 (1.12–1.58) <0.001
3–4 1.57 (1.38–1.79) <0.001
2 1.43 (1.27–1.62) <0.001
1 — —
Size of tumor (cm) 1.21 (1.10–1.34) <0.001
Number of observations in the original data set = 28,241. Number of observations used = 6438. Tumor location was included in the multivariable model but not shown here.
aIncluding but not restricted to, spindle cell carcinoma, mucoepidermoid malignancies, neuroendocrine, and mixed malignant tumors.
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surgical margins, OS remained worse after segmentectomy and 
wedge resection. A difference was not identiﬁed in patients with 
positive margins; however, the sample size in these subgroups 
was too small to draw reliable conclusions.
To further compare segmentectomy and lobectomy con-
trolling for both surgical margins and adequate lymphadenec-
tomy, we performed a multivariable analysis including only 
patients with negative margins and more than or equal toﬁve 
and seven LNs. After controlling for these factors, we did not 
identify a difference in OS in patients with negative margins 
and more than or equal to ﬁve LNs examined when comparing 
segmentectomy (n = 81) with lobectomy (n = 2888) (HR, 1.20; 
95% CI, 0.86–1.67; p = 0.277). Similarly, we did not identify 
a difference when only including patients with more than or 
equal to seven LNs examined (HR = 1.48, 95% CI: 0.98–2.23, 
p = 0.063; segmentectomy n = 44, lobectomy n = 2181). The 
relatively low number of patients undergoing segmentectomy 
in this subgroup analysis should be noted.
Finally, to better control for baseline differences between 
the two cohorts, a propensity score matching method was 
implemented with results shown in Table 5. A total of 987 
patients were matched in each treatment group and were simi-
lar in regards to all covariates (standardized difference < 0.1). 
After matching, there was no difference in 30-day mortality. 
However, both wedge resection and segmental resection were 
associated with signiﬁcantly worse OS, lower likelihood of hav-
ing more than three LN examined, and as a result signiﬁcantly 
lower rate of nodal upstaging. Wedge resection was associated 
with signiﬁcantly higher rates of positive surgical margins. 
Lastly, Kaplan–Meier survival curves in the propensity score 
matched groups are shown in Figure 1B and conﬁrmed signiﬁ-
cantly improved long-term survival with lobectomy.
DISCUSSION
An anatomical lobectomy with mediastinal LN staging 
is the current standard surgical therapy for early-stage lung 
TABLE 4. Multivariate Association with Long-Term Mortality—Interaction with Facility Type, Tumor Size, and Number of 
Lymph Nodes Examined
Covariates Level Hazard Ratio HR P Value Type 3 P Valuea
Stratiﬁed comparisons by facility type — — 0.035
  Noncomprehensive community 
cancer program/other
Wedge resection (186) vs. lobectomy (440) 1.34 (1.02–1.76) 0.032 —
Segmental resection (27) vs. lobectomy (440) 2.11 (1.24–3.60) 0.006
  Comprehensive community cancer program Wedge resection (987) vs. lobectomy (2639) 1.47 (1.32–1.64) <0.001 —
Segmental resection (129) vs. lobectomy (2639) 1.09 (0.82–1.44) 0.561
  Academic/research program Wedge resection (718) vs. lobectomy (1778) 1.73 (1.51–1.98) <0.001 —
Segmental resection (130) vs. Lobectomy (1778) 1.51 (1.16–1.96) 0.002
Stratiﬁed comparisons by tumor size 0.203
  0–1 cm Wedge resection (439) vs. lobectomy (722) 1.77 (1.45–2.16) <0.001 —
Segmental resection (51) vs. lobectomy (722) 1.24 (0.74–2.06) 0.414
  1–2 cm Wedge resection (1452) vs. lobectomy (4135) 1.47 (1.35–1.61) <0.001 —
Segmental resection (235) vs. lobectomy (4135) 1.32 (1.09–1.60) 0.004
Stratiﬁed comparisons by regional LN examined 0.655
  0–7 Wedge resection (1739) vs. lobectomy (2881) 1.50 (1.37–1.65) <0.001 —
Segmental resection (246) vs. lobectomy (2881) 1.27 (1.04–1.55) 0.020
  8+ Wedge resection (152) vs. lobectomy (1976) 1.56 (1.21–2.01) <0.001 —
Segmental resection (40) vs. lobectomy (1976) 1.58 (1.01–2.48) 0.044
Sample size for each subgroup listed in parenthesis.
aType 3 P value indicates the signiﬁcance for the interaction term in the ﬁtted model.
LN, lymph nodes.
TABLE 5. Comparison of Primary and Secondary Outcomes by Extent of Resection in Propensity Score Matched Samples
Outcome
Extent of Surgical Resection
Wedge Resection, n = 987 Segmentectomy, n = 987 Lobectomy, n = 987
30-Day mortality 0.87 (0.41–1.82), p = 0.706 1.13 (0.57–2.27). p = 0.724 —
Overall survivala 1.70 (1.29–2.26), p < 0.001 1.45 (1.10–1.91), p = 0.009 —
Positive surgical margins 2.02 (1.13–3.63), p = 0.018 1.29 (0.69–2.43), p = 0.426 —
> 3 LN examined 0.07 (0.05–0.09), p < 0.001 0.18 (0.14–0.22), p < 0.001 —
Positive regional LN 0.39 (0.24–0.63), p < 0.001 0.59 (0.38–0.89), p = 0.013 —
aOverall survival analysis limited to patients treated between 2003 and 2006, n = 209 per group. Overall survival reported as hazard ratio. Remaining variables reported as odds 
ratio with 95% conﬁdence intervals.
LN, lymph nodes.
1632 Copyright © 2015 by the International Association for the Study of Lung Cancer
Khullar et al. Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015
cancer. This is based on the randomized trial conducted by 
the Lung Cancer Study Group (LCSG).2 However, sublobar 
resections do offer several potential advantages: preserva-
tion of pulmonary function, greater application of minimally 
invasive surgical techniques, and increased likelihood of 
curative surgery in the event of a second primary lung can-
cer. Concerns of long-term oncologic efﬁcacy raised by the 
LCSG have relegated the utilization of sublobar resection 
to patients with limited cardiopulmonary reserve. Similar to 
the results of the LCSG, results of our analysis of the NCDB 
found signiﬁcantly worse survival after sublobar resections. 
Furthermore, propensity score matching was used to account 
for differences in baseline patient characteristics among the 
three surgical therapies. Results of this analysis showed no 
difference in 30-day mortality, with signiﬁcantly worse OS, 
lower likelihood of having adequate numbers of LN examined, 
and lower nodal upstaging rates after both wedge and segmen-
tal resections. Furthermore, wedge resection was associated 
with signiﬁcantly increased likelihood of having positive sur-
gical margins. However, when comparing only patients with 
both negative margins and adequate numbers of LNs exam-
ined, no difference was identiﬁed in OS between segmentec-
tomy and lobectomy. This ﬁnding may represent equivalency 
between segmentectomy and lobectomy in this highly selected 
subgroup of patients or may be because of underpowering of 
this subgroup analysis.
To date, the LCSG trial is the only published prospec-
tive randomized comparison of lobectomy and sublobar resec-
tion, including 267 patients with T1N0 (<3 cm; stage IA) lung 
cancers.2 Findings of this study demonstrated an increase in 
local recurrence rates (17.2% vs. 6.4%) with sublobar resec-
tions and a trend toward worse OS. However, more contem-
porary studies have questioned these results. Several single 
institution series have consistently demonstrated lower mor-
bidity and mortality rates and preserved pulmonary function 
for sublobar resections compared with lobectomy.4–9
In addition, several analyses of survival data from the 
SEER Program have been reported.9–12 A large observational 
comparison from a clinical registry such as the NCDB or 
SEER, while subject to treatment selection bias, can supple-
ment randomized trials with greater numbers, greater gener-
alizability, and more contemporary data that can be regularly 
updated. Analysis of SEER data, by Wisnivesky et al.,9 looked 
at 1165 patients with tumors less than or equal to 2 cm with 
propensity score adjustments and found equivalent OS and 
disease-free survival between lobectomy and sublobar resec-
tion. Similarly, Kates et al.10 examined SEER data in patients 
with tumors less than or equal to 1 cm between 1988 and 2005, 
688 with sublobar resection and 1402 with lobectomy. After 
propensity score matching, they also found no difference in 
OS or lung cancer-speciﬁc survival. However, Whitson et al.12 
examined SEER data in stage I patients with only squamous 
cell and adenocarcinomas of all sizes, undergoing lobectomy 
(13,892 patients) or segmentectomy (581 patients) between 
1998 and 2007. They found signiﬁcantly better OS after 
lobectomy, even after stratifying by tumor size.
The underlying reason for the conflicting results of 
our analysis and previous studies is difﬁcult to determine. 
Our large sample size may allow for better identiﬁcation of 
survival differences. Furthermore, our study used propensity 
matching to account for identiﬁed differences in patient and 
tumor characteristics. In addition, in our analysis, patients 
undergoing limited resection were signiﬁcantly more likely 
to have a positive margin or inadequate lymphadenectomy, 
which could be contributing to worse OS. Finally, the large 
size and nationwide distribution of the NCDB reflects care 
given to nearly 70% of newly diagnosed cancer patients 
annually. As a result, this analysis may be more reflective of 
the general care of patients with early-stage NSCLC in the 
United States.
Furthermore, although several previous single institution 
series have suggested equivalent survival for sublobar resec-
tion for smaller tumors or with adequate lymphadenectomy, 
our results did not support this conclusion. Subgroup analy-
sis in this study conﬁrmed improved survival after lobectomy 
when compared with both sublobar approaches for tumors 1 
to 2 cm. For tumors 1 cm or smaller, lobectomy was superior 
to wedge resection. Regardless, no signiﬁcant interaction was 
identiﬁed between tumor size and extent of resection when 
evaluating the end point of OS. Similarly, survival after lobec-
tomy was better than sublobar approaches regardless of the 
number of LN evaluated. In other words, patients treated with 
wedge resection and adequate mediastinal LN evaluation still 
fared worse than those who underwent lobectomy. Finally, as 
the majority of these single institution series were performed 
at academic facilities, we performed a subgroup analysis of 
OS stratiﬁed by treatment facility. With the exception of seg-
mentectomy performed at comprehensive community cancer 
programs, survival after lobectomy remained superior regard-
less of academic or community treatment facility.
The major limitation of this analysis is its retrospective 
observational nature, which subjects it to possible unmea-
sured confounding. However, with the inclusion of 15 vari-
ables and nearly 2500 patients in each cohort, this study 
represents a well-balanced analysis of these three treatment 
methods. In addition, we are limited to patients treated in 
2006 and earlier as long-term survival data is not available 
in the NCDB beyond that date. Given the wider adoption of 
positron emission tomography-computed tomography scan-
ning and minimally invasive thoracoscopic techniques, results 
may be slightly different in a more contemporary cohort. 
Furthermore, data regarding ground glass opacities and sub-
solid nodules representing minimally invasive adenocarcino-
mas are unavailable in the NCDB. As a result, the distribution 
of these patients within the study cohort is unknown and could 
not be accounted for. It is possible that if there is a higher pro-
portion of patients with ground glass opacities in one of the 
cohorts, this may have confounded the results.
Finally, no data are available on pulmonary function, 
preoperative functional status, or speciﬁc comorbidities in 
the NCDB other than the Charlson/Deyo comorbidity index. 
As a higher Charlson/Deyo comorbidity score cannot differ-
entiate between the 10 included medical comoribidities, it is 
impossible to completely control for medical comorbidities/
confounders. As a result, despite careful propensity match-
ing, there is still the potential for selection bias between the 
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cohorts as patients with worse pulmonary function testing or 
fraility are more likely to undergoing a wedge or segmental 
resection. Ultimately, a prospective, randomized study will 
be needed to determine the optimal surgical strategy. Based 
on these previous studies, the National Cancer Institute has 
sponsored Cancer and Leukemia Group B 140503, a phase III 
randomized trial comparing outcomes between lobectomy and 
sublobar resection for lung cancers smaller than 2 cm.
In summary, this analysis of the NCDB showed 
improved OS after lobectomy in comparison with both 
wedge resection and segmentectomy for patients with clini-
cal T1A N0 NSCLC, regardless of treatment facility type, 
extent of resection, or tumor size (after wedge resection). 
Furthermore, patients undergoing wedge resection were 
more likely to have inadequate LN evaluation and to have 
positive margins. These results conﬁrm that anatomical 
lobectomy should remain the standard of care treatment for 
stage IA NSCLC at this point. However, if margin status and 
LN evaluation are controlled, segmentectomy may be equiv-
alent to lobectomy. Given the limitations of a retrospective 
database analysis, further prospective study is still needed to 
ultimately determine the optimal extent of surgery for early-
stage lung cancer.
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